Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 8:14:1132692.
doi: 10.3389/fimmu.2023.1132692. eCollection 2023.

Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil

Mengge Ding  1 , Chao Deng  1 , Xianling Liu  1 , Shun Jiang  1 , Yuan Gao  2 , Dan Fan  1 , Yiguang Zhou  1 , Jiangbo He  1 , Chaoyuan Liu  1
Affiliations
Case Reports

Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil

Mengge Ding et al. Front Immunol. .

Abstract

The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain-Barré syndrome (GBS), a rare type of irAE. Most GBS patients can recover spontaneously due to the self-limited nature of the disease, but severe cases can result in respiratory failure or even death. Here we report a rare case of GBS occurring in a 58-year-old male patient with non-small cell lung cancer (NSCLC) who developed muscle weakness and numbness of the extremities during chemotherapy combined with KN046, a PD-L1/CTLA-4 bispecific antibody. Despite receiving methylprednisolone and γ-globulin, the patient's symptoms did not improve. However, there was significant improvement after treatment with mycophenolate mofetil (MM) capsules, which is not a routine regimen for GBS. To the best of our knowledge, this is the first reported case of ICIs-induced GBS that responded well to mycophenolate mofetil instead of methylprednisolone or γ-globulin. Thus, it provides a new treatment option for patients with ICIs-induced GBS.

Keywords: Guillain–Barré syndrome; KN046; immune checkpoint inhibitors; immune-related adverse events; mycophenolate mofetil.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The treatment procedure of the patient. (A) Methylprednisolone, (B) IVIG, (C) Mycophenolate mofetil capsules; *ivgtt, #po. ① Day of admission. ② Day of discharged.
See this image and copyright information in PMC

References

    1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11(1):3801. doi: 10.1038/s41467-020-17670-y - DOI - PMC - PubMed
    1. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–80. doi: 10.1038/s41571-019-0218-0 - DOI - PubMed
    1. Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S, et al. Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open 5(4):e227722. doi: 10.1001/jamanetworkopen.2022.7722 - DOI - PMC - PubMed
    1. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré Syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–82. doi: 10.1038/nrneurol.2014.121 - DOI - PubMed
    1. Harrison RA, Tummala S, de Groot J. Neurologic toxicities of cancer immunotherapies: a review. Curr Neurol Neurosci Rep 20(7):27. doi: 10.1007/s11910-020-01038-2 - DOI - PubMed

Publication types